The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Sarah P. Blagden, Erica De Zan et al.|Clinical Cancer Research|2021Cited by 44
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Udai Banerji, Ruth Plummer et al.|British Journal of Cancer|2023Cited by 36
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.Elizabeth Ruth Plummer, Udai Banerji, Rebecca Kristeleit et al.|Journal of Clinical Oncology|2019Cited by 31
ATTAINMENT: A phase Ib trial of MDX-124, a first-in-class annexin-A1 targeting antibody, alone and in combination with anti-cancer treatments, in patients with advanced solid tumors.Daniel H. Palmer, Sarah P. Blagden, Stefan N. Symeonides et al.|Journal of Clinical Oncology|2024Cited by 4
Abstract CT136: NUC-7738, a novel ProTide transformation of 3′-deoxyadenosine, in patients with advanced solid tumorsRuth Plummer, Sarah P. Blagden, Farasat Kazmi et al.|Cancer Research|2021Cited by 2